Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
710 (USA) · Dr. Silva
consented 2014-03-29
AEs
2
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate SKIN IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-18 (study day 21.0); relationship: POSSIBLE
severe
assessed
Severe SKIN IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-18 (study day 21.0); relationship: POSSIBLE
Data queries
No data queries.